Medical Xpress December 7, 2021
Aduhelm, the first new Alzheimer’s drug in 18 years, could easily become the best-selling drug in Medicare, despite its potential massive cost and tremendous uncertainty about whether the drug even works, says Rachel Sachs, the Treiman Professor of Law and nationally renowned expert on drug pricing and health policy.
Biogen, which created the drug, halted its Aduhelm clinical trials in 2019 when an examination of early trial data suggested that the drug did not work. But Biogen researchers later analyzed the trial results further and argued that high-dose patients in one of the two trials had benefited from the drug, experiencing a 22% reduction in clinical decline. Given the uncertain results and that similar drugs have proven ineffective in the...